NCT02903914 · OUTCOME

RP2D of INCB001158 in Combination With Pembrolizumab

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors · Source last updated 2025-08-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: milligrams
Interval / dispersion: Not reported
Time frame: 12 weeks

What was measured

INCB001158 was dosed orally BID.

Analysis population: Safety Population

Groups in this outcome

INCB001158 as Combination Therapy at 50, 75, and 100 mg BID

INCB001158 administered orally in patients at 50, 75, and 100 mg doses BID with advanced/metastatic solid tumors in combination with pembrolizumab (200 mg IV Q3W)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
INCB001158 as Combination Therapy at 50, 75, and 100 mg BID	33

Reported measurements

Source class 1

Values in milligrams · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
INCB001158 as Combination Therapy at 50, 75, and 100 mg BID	100	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
100

denoms

counts
group Id
OG000
value
33
units
Participants

description

INCB001158 was dosed orally BID.

groups

description
INCB001158 administered orally in patients at 50, 75, and 100 mg doses BID with advanced/metastatic solid tumors in combination with pembrolizumab (200 mg IV Q3W)
id
OG000
title
INCB001158 as Combination Therapy at 50, 75, and 100 mg BID

param Type

NUMBER

population Description

Safety Population

reporting Status

POSTED

time Frame

12 weeks

title

RP2D of INCB001158 in Combination With Pembrolizumab

type

SECONDARY

unit Of Measure

milligrams

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice